中草药

基于代谢重编程及相关信号途径探讨中药干预结直肠癌的研究进展

PDF下载

中草药 | 综述 2026,57(6): 2326-2336

收起

中草药 |综述 2026 , 57 (6) : 2326 -2336

基于代谢重编程及相关信号途径探讨中药干预结直肠癌的研究进展

全屏

王敦方¹, 冯雪¹, 张彩娟¹, 刘海帆², 刘鉴瑶¹, 刘滨¹, 朱琳¹, 孙绮悦¹, 马旭冉³, 杨伟鹏¹

作者信息

作者简介:

王敦方: 王敦方,博士,助理研究员,从事中药药理学研究。E-mail:wdf122644@126.com

Research progress on traditional Chinese medicine intervention in colorectal cancer based on metabolic reprogramming and related signal pathways

WANG Dunfang, FENG Xue, ZHANG Caijuan, LIU Haifan, LIU Jianyao, LIU Bin, ZHU Lin, SUN Qiyue, MA Xuran, YANG Weipeng

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.06.026

文章导航

摘要

收起

结直肠癌作为全球高发的消化道恶性肿瘤，其发病率占世界排名前列。代谢重编程是结直肠癌的关键特征之一，涉及糖、脂质、氨基酸代谢的异常重构，并受磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白、缺氧诱导因子-1α、Myc原癌基因等信号通路精密调控。近年来，靶向代谢重编程已成为结直肠癌治疗的新兴策略。然而，化学药单靶点抑制剂面临耐药性等挑战。中医药在干预结直肠癌代谢重编程方面展现出多成分、多靶点的独特优势。在简要概述结直肠癌代谢重编程核心机制的基础上，重点系统综述了中药有效成分（小檗碱、人参皂苷、汉黄芩素等）及复方制剂（黄芩汤、乌梅丸等）通过调控关键代谢酶与信号通路，逆转Warburg效应、抑制脂肪酸从头合成、干预氨基酸代谢等，从而抑制结直肠癌进展的作用机制，为中医药防治结直肠癌提供新的研究思路和理论依据。

关键词

结直肠癌 / 糖代谢 / 脂肪酸代谢 / 氨基酸代谢 / 代谢重编程 / 代谢通路 / 小檗碱 / 人参皂苷 / 汉黄芩素

Abstract

收起

Colorectal cancer (CRC) is a highly prevalent malignant tumor of the digestive tract globally, ranking among the top in terms of incidence worldwide. Metabolic reprogramming is a key hallmark of CRC, involving the abnormal remodeling of glucose, lipid, and amino acid metabolism, which is precisely regulated by signaling pathways such as phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin, hypoxia inducible factor-1α, and c-Myc. In recent years, targeting metabolic reprogramming has emerged as a novel strategy for CRC treatment. However, single-target chemical inhibitors face challenges like drug resistance. Traditional Chinese medicine (TCM) demonstrates unique advantages in intervening in CRC metabolic reprogramming through its multi-component and multi-target characteristics. Based on a brief overview of the core mechanisms of metabolic reprogramming in CRC, this review systematically summarizes the mechanisms by which active TCM components (berberine, ginsenosides, wogonin, etc.) and TCM formulas (Huangqin Decoction, Wumei Wan, etc.) inhibit CRC progression by regulating key metabolic enzymes and signaling pathways, thereby reversing the Warburg effect, inhibiting de novo fatty acid synthesis, and intervening in amino acid metabolism. This article aims to offer new research ideas and a theoretical basis for the prevention and treatment of CRC with TCM.

Key words

colorectal cancer / glucose metabolism / fatty acid metabolism / amino acid metabolism / metabolic reprogramming / metabolic pathway / berberine / ginsenosides / wogonin

引用本文

王敦方, 冯雪, 张彩娟, 刘海帆, 刘鉴瑶, 刘滨, 朱琳, 孙绮悦, 马旭冉, 杨伟鹏. 基于代谢重编程及相关信号途径探讨中药干预结直肠癌的研究进展. 中草药, 2026 , 57 (6) : 2326 -2336 . DOI: 10.7501/j.issn.0253-2670.2026.06.026

WANG Dunfang, FENG Xue, ZHANG Caijuan, LIU Haifan, LIU Jianyao, LIU Bin, ZHU Lin, SUN Qiyue, MA Xuran, YANG Weipeng. Research progress on traditional Chinese medicine intervention in colorectal cancer based on metabolic reprogramming and related signal pathways[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (6) : 2326 -2336 . DOI: 10.7501/j.issn.0253-2670.2026.06.026

基金

收起

国家自然科学青年基金资助项目 (82304835); 中央级公益性科研院所基本科研业务费专项资金资助 (ZZ19-XRZ-092); 中国中医科学院科技创新工程重点协同攻关项目 (CI2023C054YLL); 国家自然科学基金面上项目 (82074328); 山东省自然科学基金青年面上专项类别 (ZR2025QC938)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

季双双, 龙思丹, 杨洋, 等. 结直肠“正常黏膜-腺瘤-腺癌”序列转化的靶向基因筛选及防治中药预测[J]. 中草药, 2025, 56(3): 933-946.
Angelou A, Andreatos N, Antoniou E, et al. A novel modification of the AOM/DSS model for inducing intestinal adenomas in mice[J]. Anticancer Res, 2018, 38(6): 3467-3470.
Bensard C L, Wisidagama D R, Olson K A, et al. Regulation of tumor initiation by the mitochondrial pyruvate carrier[J]. Cell Metab, 2020, 31(2): 284-300.
Dekker E, Tanis P J, Vleugels J L A, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480.
Chaves-Perez A, Millman S E, Janaki-Raman S, et al. Metabolic adaptations direct cell fate during tissue regeneration[J]. Nature, 2025, 643(8071): 468-477.
Tarrado-Castellarnau M, Foguet C, Tarragó-Celada J, et al. Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells[J]. Oncogene, 2025, 44(36): 3386-3406.
Zhao X H, Li K, Chen M Y, et al. Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities[J]. Biomed Pharmacother, 2023, 162: 114601.
Wu Z D, Zuo M L, Zeng L, et al. OMA1 reprograms metabolism under hypoxia to promote colorectal cancer development[J]. EMBO Rep, 2021, 22(1): e50827.
李若男, 陈喜, 赵李娜, 等. 基于网络药理学吴茱萸治疗结直肠癌作用机制探讨及实验验证[J]. 药物评价研究, 2024, 47(1): 38-45.
张璐, 李波旺, 张玉丽, 等. 基于网络药理学与实验验证的薏苡附子败酱散抗小鼠自发性结直肠癌肿瘤作用机制研究[J]. 药物评价研究, 2025, 48(4): 887-898.
孙清秀, 蒲凤华. β-榄香烯治疗结直肠癌作用机制研究进展[J]. 现代药物与临床, 2024, 39(5): 1354-1359.
Kooshan Z, Cárdenas-Piedra L, Clements J, et al. Glycolysis, the sweet appetite of the tumor microenvironment[J]. Cancer Lett, 2024, 600: 217156.
Ganapathy-Kanniappan S, Geschwind J H. Tumor glycolysis as a target for cancer therapy: Progress and prospects[J]. Mol Cancer, 2013, 12: 152.
Wu J Y, Hu L R, Wu F P, et al. Poor prognosis of hexokinase 2 overexpression in solid tumors of digestive system: A Meta-analysis[J]. Oncotarget, 2017, 8(19): 32332-32344.
Israelsen W J, Vander Heiden M G. Pyruvate kinase: Function, regulation and role in cancer[J]. Semin Cell Dev Biol, 2015, 43: 43-51.
Wang J Y, Zhu M X, Zhu J H, et al. HES1 promotes aerobic glycolysis and cancer progression of colorectal cancer via IGF2BP2-mediated GLUT1 m⁶A modification[J]. Cell Death Discov, 2023, 9(1): 411.
Amann T, Maegdefrau U, Hartmann A, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis[J]. Am J Pathol, 2009, 174(4): 1544-1552.
Chen C, Zhu Y H, Huang J N. Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer[J]. J Cancer Res Ther, 2018, 14(Suppl): S336-S340.
Alberghina L. The Warburg effect explained: Integration of enhanced glycolysis with heterogeneous mitochondria to promote cancer cell proliferation[J]. Int J Mol Sci, 2023, 24(21): 15787.
Mazzarelli P, Pucci S, Bonanno E, et al. Carnitine palmitoyltransferase I in human carcinomas: A novel role in histone deacetylation?[J]. Cancer Biol Ther, 2007, 6(10): 1606-1613.
Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation[J]. Science, 2012, 336(6084): 1040-1044.
Luengo A, Gui D Y, Vander Heiden M G. Targeting metabolism for cancer therapy[J]. Cell Chem Biol, 2017, 24(9): 1161-1180.
Wang Z Q, Lu Z, Lin S L, et al. Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion[J]. Immunity, 2022, 55(9): 1748.
Lin Y Y, Zhang Y H, Huang T Z, et al. Arginine deprivation induces quiescence and confers vulnerability to ferroptosis in colorectal cancer[J]. Cancer Res, 2025, 85(9): 1663-1679.
Pang B R, Wu H. Metabolic reprogramming in colorectal cancer: A review of aerobic glycolysis and its therapeutic implications for targeted treatment strategies[J]. Cell Death Discov, 2025, 11(1): 321.
Qin R, Fan X R, Huang Y, et al. Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance[J]. Transl Oncol, 2024, 50: 102156.
Li M Z, Wu X, Pan Y W, et al. mTORC2-Akt signaling to PFKFB2 activates glycolysis that enhances stemness and tumorigenicity of intestinal epithelial cells[J]. FASEB J, 2024, 38(5): e23532.
Zheng Y N, Lou S Y, Lu J, et al. Selective PI3Kδ inhibitor TYM-3-98 suppresses Akt/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer[J]. Cell Death Dis, 2024, 15(7): 474.
Pan G T, Zhang P, Chen A Y, et al. Aerobic glycolysis in colon cancer is repressed by naringin via the HIF1Α pathway[J]. J Zhejiang Univ Sci B, 2023, 24(3): 221-231.
Ni T, He Z H, Dai Y Y, et al. Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism[J]. Cell Death Dis, 2017, 8(6): e2865.
Zhao L Q, Yu N Y, Zhai Y J, et al. The ubiquitin-like protein UBTD1 promotes colorectal cancer progression by stabilizing c-Myc to upregulate glycolysis[J]. Cell Death Dis, 2024, 15(7): 502.
McLeod H L, Murray G I. Tumour markers of prognosis in colorectal cancer[J]. Br J Cancer, 1999, 79(2): 191-203.
Lee Y J, Han Y J, Oh J J, et al. OTOP3 functions as an oncogenic regulator of ferroptosis-mediated colorectal cancer progression[J]. Genes Genomics, 2025, 47(8): 911-922.
张晓莉. 谷糠多酚通过c-Myc/miR-149/Akt调控鞘糖脂代谢逆转结肠癌耐药的分子机制[D]. 太原: 山西大学, 2021.
张兵, 李恒, 吴安皓, 等. miR-149与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2019, 27(15): 2776-2779.
Martin-Vega A, Cobb M H. ERK1/2-MAPK signaling: Metabolic, organellar, and cytoskeletal interactions[J]. Curr Opin Cell Biol, 2025, 95: 102526.
Yang W W, Zheng Y H, Xia Y, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect[J]. Nat Cell Biol, 2012, 14(12): 1295-1304.
Liu H, Chen X T, Wang P F, et al. PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis[J]. Cell Death Dis, 2024, 15(2): 170.
Qiu X X, Wang A, Wang J H, et al. Mitochondrial metabolic reprogramming in colorectal cancer: Mechanisms of resistance and future clinical interventions[J]. Cell Death Discov, 2025, 11(1): 375.
Hou Y C, Zhang X T, Yao H, et al. METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53-wild-type cells[J]. EMBO Rep, 2023, 24(4): e56325.
Huang Y D, Xiong C, Wang C M, et al. p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP[J]. Cell Rep, 2023, 42(11): 113426.
Wang X Y, Li Y Y, Li Y, et al. AMPK-dependent Parkin activation suppresses macrophage antigen presentation to promote tumor progression[J]. Sci Adv, 2025, 11(12): eadn8402.
Rao X S, Cong X X, Gao X K, et al. AMPK-mediated phosphorylation enhances the auto-inhibition of TBC1D17 to promote Rab5-dependent glucose uptake[J]. Cell Death Differ, 2021, 28(12): 3214-3234.
Dai W X, Xu Y, Mo S B, et al. GLUT3 induced by AMPK/CREB1 axis is key for withstanding energy stress and augments the efficacy of current colorectal cancer therapies[J]. Signal Transduct Target Ther, 2020, 5(1): 177.
Pham H, Eibl G, Vincenti R, et al. 15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice[J]. Mol Carcinog, 2008, 47(6): 466-477.
聂芳, 赵贤元, 余跃天, 等. PPARα/COX-2/PGE₂通路在人结肠癌耐药细胞中的作用研究[J]. 现代消化及介入诊疗, 2015, 20(6): 586-591.
Muthusami S, Ramachandran I K, Babu K N, et al. Role of inflammation in the development of colorectal cancer[J]. Endocr Metab Immune Disord Drug Targets, 2021, 21(1): 77-90.
Mao Y X, Xia Z Y, Xia W J, et al. Metabolic reprogramming, sensing, and cancer therapy[J]. Cell Rep, 2024, 43(12): 115064.
Nicolini A, Ferrari P. Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy[J]. Front Immunol, 2024, 15: 1353787.
Liu Y, Wu Z F, Li Y K, et al. Metabolic reprogramming and interventions in angiogenesis[J]. J Adv Res, 2025, 70: 323-338.
Li Y, He C, Shen A N, et al. pH of microenvironment directly modulates the phenotype and function of cancer-associated fibroblasts[J]. ACS Omega, 2025, 10(4): 3937-3943.
Wang R, Li W M, Lv Y Q, et al. Colorectal cancer cells-derived exosomal PIK3CA mutation DNA promotes tumor metastasis by activating fibroblast and affecting tumor metastatic microenvironment[J]. Adv Sci, 2025, 12(27): 2501792.
Ren F L, Meng L, Zheng S Z, et al. Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4⁺ and CD8⁺ T cells[J]. J Exp Clin Cancer Res, 2025, 44(1): 33.
Ren Y M, Zhuang Z Y, Xie Y H, et al. BCAA-producing Clostridium symbiosum promotes colorectal tumorigenesis through the modulation of host cholesterol metabolism[J]. Cell Host Microbe, 2024, 32(9): 1519-1535.
Fantin V R, St-Pierre J, Leder P. Attenuation of LDH-a expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance[J]. Cancer Cell, 2006, 9(6): 425-434.
Le A, Cooper C R, Gouw A M, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression[J]. Proc Natl Acad Sci USA, 2010, 107(5): 2037-2042.
Falchook G, Infante J, Arkenau H T, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors[J]. EClinicalMedicine, 2021, 34: 100797.
Zhou W J, Zhang J, Yang H L, et al. Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism[J]. Cell Commun Signal, 2019, 17(1): 99.
Vander Heiden M G. Targeting cancer metabolism: A therapeutic window opens[J]. Nat Rev Drug Discov, 2011, 10(9): 671-684.
Wang D F, Zhu L, Liu H F, et al. Huangqin Tang alleviates colitis-associated colorectal cancer via amino acids homeostasisand PI3K/Akt/mTOR pathway modulation[J]. J Ethnopharmacol, 2024, 334: 118597.
王国娟, 朱柰澄, 晏玉薇, 等. 中医药调控结直肠炎-癌转化的作用机制研究进展[J/OL]. 辽宁中医杂志, (2025-02-14)[2025-10-12]. https://link.cnki.net/urlid/21. 1128.R.20250214.1302.074.
王华苗, 张春泽. 中医药防治结直肠癌复发转移的研究进展[J]. 药学学报, 2025, 60(3): 693-699.
褚雪镭. 基于肠道菌群-胆汁酸-免疫轴探讨养肝益中方防治结直肠癌肝转移的作用机制[D]. 北京: 中国中医科学院, 2024.
White E. Exploiting the bad eating habits of Ras-driven cancers[J]. Genes Dev, 2013, 27(19): 2065-2071.
Weinberg F, Hamanaka R, Wheaton W W, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity[J]. Proc Natl Acad Sci USA, 2010, 107(19): 8788-8793.
Gao W H, Li Y L, Chen L H, et al. Berberine-cinnamic acid co-crystal effect in ameliorating hyperlipidemia might be regulated through the PI3K/Akt/mTOR/SREBP-1 signaling pathway[J]. FEBS Open Bio, 2025, 16(1): 145-160.
周良春, 吕佳昕, 王冬园. 小檗碱抗肿瘤药理作用机制及临床应用进展[J]. 医药导报, 2025, 44(8): 1229-1235.
杨庆万, 周松, 陈春兰, 等. 基于代谢组学探索小檗碱对APC^min/+小鼠结直肠腺瘤的作用机制[J]. 中草药, 2024, 55(22): 7736-7745.
Liu X, Ji Q, Ye N J, et al. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE₂ mediated JAK2/STAT3 signaling pathway[J]. PLoS One, 2015, 10(5): e0123478.
Chen H T, Zhang F, Zhang J, et al. A holistic view of berberine inhibiting intestinal carcinogenesis in conventional mice based on microbiome-metabolomics analysis[J]. Front Immunol, 2020, 11: 588079.
陆佳. 钩藤碱抑制PDHK1抗结直肠癌转移的分子机制研究[D]. 天津: 天津中医药大学, 2022.
刘璨, 刘艾鑫, 姜昌镐. 木兰花碱通过ROS/KRAS/ AMPK抑制结直肠癌SW480细胞干性特征和糖酵解[J]. 中国免疫学杂志, 2022, 38(3): 344-347.
李佳威, 李芳芳, 金丹. 人参皂苷衍生物AD-1对结肠癌细胞株HT-29的影响及其机制的研究[A] // 第十四届全国免疫学学术大会论文摘要汇编[C]. 延吉: 中国免疫学会, 2021: 289.
崔亚茹, 王慧玲, 陈兰英, 等. 白头翁皂苷PSA对SW480人结直肠癌细胞糖酵解途径关键蛋白及调节因子HIF-1α的影响[J]. 中成药, 2019, 41(12): 2887-2892.
杨欣, 贾静, 谢欣序, 等. 白头翁皂苷B4调控结肠癌小鼠脂肪酸代谢重编程作用研究[J]. 中国中药杂志, 2023, 48(9): 2325-2333.
朱文宇, 张红卫, 唐德才, 等. 绞股蓝皂苷LI通过代谢脂肪酸通路下调肉碱棕榈酰转移酶1B抑制结肠癌生长[J]. 实用医学杂志, 2025, 41(2): 162-169.
冯慧, 周婷婷, 黎子文, 等. α-常春藤皂苷调控SNX10介导的谷氨酰胺代谢抑制肠上皮细胞恶性转化研究[J]. 中草药, 2023, 54(7): 2135-2143.
国利超. 异黄酮类化合物与GLUT1抑制剂BAY-876对结直肠癌的协同抑制作用研究[D]. 石家庄: 河北师范大学, 2024.
贾丹. 联合新型靶标鉴定技术及多组学分析的中药活性成分药效机制研究[D]. 上海: 中国人民解放军海军军医大学, 2018.
Li X Y, Khan I, Huang G X, et al. Kaempferol acts on bile acid signaling and gut microbiota to attenuate the tumor burden in APC^min/+ mice[J]. Eur J Pharmacol, 2022, 918: 174773.
Han P H, Chu S Z, Shen J, et al. Quercetin-derived microbial metabolite DOPAC potentiates CD8⁺ T cell anti-tumor immunity via Nrf2-mediated mitophagy[J]. Cell Metab, 2025, 37(12): 2438-2454.
江楠, 马欣. 近20年穿心莲内酯药理作用研究进展[J]. 辽宁中医药大学学报, 2024, 26(12): 203-208.
郭佳星, 王振堂, 林宇, 等. PBK/TOPK通过改变糖酵解关键酶表达水平增加结直肠癌细胞放射敏感性[J]. 现代肿瘤医学, 2022, 30(7): 1167-1171.
Li X F, Tian R F, Liu L, et al. Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells[J]. J Int Med Res, 2020, 48(8): 0300060520946169.
Li C, Li Z F, Zhang T J, et al. ¹H-NMR-based metabolomics reveals the antitumor mechanisms of triptolide in BALB/c mice bearing CT26 tumors[J]. Front Pharmacol, 2019, 10: 1175.
Kim H J, Kim I S, Rehman S U, et al. Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism[J]. Bioorg Med Chem Lett, 2017, 27(8): 1826-1830.
李岩溪, 王永鹏, 林涛, 等. 6-姜酮酚对结直肠癌细胞增殖、凋亡和糖酵解的影响及机制研究[J]. 解剖科学进展, 2020, 26(3): 280-283.
Liu W B, Li W, Liu H D, et al. Xanthohumol inhibits colorectal cancer cells via downregulation of hexokinases II-mediated glycolysis[J]. Int J Biol Sci, 2019, 15(11): 2497-2508.
Wang M Y, Qu L Q, Du X Y, et al. Natural products and derivatives targeting metabolic reprogramming in colorectal cancer: A comprehensive review[J]. Metabolites, 2024, 14(9): 490.
Zhang N, Gao M, Wang Z H, et al. Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level[J]. J Pharm Biomed Anal, 2021, 201: 114129.
Alrafas H R, Busbee P B, Chitrala K N, et al. Alterations in the gut microbiome and suppression of histone deacetylases by resveratrol are associated with attenuation of colonic inflammation and protection against colorectal cancer[J]. J Clin Med, 2020, 9(6): 1796.
Zhang K, Zhou X T, Wang J Q, et al. Dendrobium officinale polysaccharide triggers mitochondrial disorder to induce colon cancer cell death via ROS-AMPK-autophagy pathway[J]. Carbohydr Polym, 2021, 264: 118018.
Wei X, Cheng F E, Liu J Y, et al. Sparassis latifolia polysaccharides inhibit colon cancer in mice by modulating gut microbiota and metabolism[J]. Int J Biol Macromol, 2023, 232: 123299.
Ren W K, Ban J F, Xia Y Y, et al. Echinacea purpurea-derived homogeneous polysaccharide exerts anti-tumor efficacy via facilitating M1 macrophage polarization[J]. Innovation, 2023, 4(2): 100391.
Qin Z Y, Yuan X Y, Liu J, et al. Albuca bracteata polysaccharides attenuate AOM/DSS induced colon tumorigenesis via regulating oxidative stress, inflammation and gut microbiota in mice[J]. Front Pharmacol, 2022, 13: 833077.
郭亭君, 袁星, 邹昀桓, 等. 经典名方黄芩汤的现代研究进展[J]. 中草药, 2025, 56(4): 1414-1427.
Liu Y J, Zhang Q, Lu L, et al. Huang-Qin Decoction alleviates deoxycholic acid-induced colorectal cancer in mice by regulating gut microbiota[J]. J Ethnopharmacol, 2025, 346: 119715.
赵冠宇, 辛蕊华, 仇正英, 等. 基于NLRP3/Caspase-1/ GSDMD信号通路研究乌梅丸对溃疡性结肠炎小鼠结肠上皮细胞焦亡的作用机制[J]. 中草药, 2023, 54(24): 8086-8093.
Cui H T, Jin Y T, Wang N, et al. Mechanic evaluation of Wu-Mei-Pill on colitis-associated colorectal cancer: An integrated transcriptomics, metabolomics, and experimental validation study[J]. Phytomedicine, 2024, 128: 155509.
支景琳, 冯媛媛, 刘宁宁, 等. 乌梅丸激活STING促进CD8⁺ T细胞浸润活化抗结直肠癌的机制[J]. 上海中医药杂志, 2025, 59(5): 1-7.
李雪莹, 王佐梅, 姚欣卉, 等. 四神丸药理作用及临床应用研究进展[J]. 辽宁中医药大学学报, 2021, 23(4): 122-126.
刘宝通. 四神丸加味用于大肠癌围手术期治疗的临床研究[D]. 沈阳: 辽宁中医药大学, 2016.
蒋义芳, 黄娅, 肖冲, 等. 四神丸含药血清抑制人结肠癌细胞有氧糖酵解的效应及机制[J]. 中国实验方剂学杂志, 2023, 29(19): 26-33.
易崇勤, 孙建宁, 张家俊, 等. 四君子汤调整小鼠运化功能紊乱的实验研究[J]. 中国中西医结合杂志, 1997, 17(1): 42-44.
胡学谦, 朱童, 王丹, 等. 消痰通腑方对结肠癌SW480细胞磷脂酶A2、环氧合酶2表达及细胞生物学行为的影响[J]. 中国中医药信息杂志, 2016, 23(8): 50-53.
周肸. 固正消癌方对结肠癌糖代谢作用机制研究[D]. 南京: 南京中医药大学, 2021.
Cai K, Cao X Y, Chen F, et al. Xianlian Jiedu Decoction alleviates colorectal cancer by regulating metabolic profiles, intestinal microbiota and metabolites[J]. Phytomedicine, 2024, 128: 155385.
Gou H Y, Su H, Liu D H, et al. Traditional medicine Pien Tze Huang suppresses colorectal tumorigenesis through restoring gut microbiota and metabolites[J]. Gastroenterology, 2023, 165(6): 1404-1419.

2026年第57卷第6期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.06.026

接收时间：2025-09-16
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-09-16

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.06.026

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT